Related Experiment Video
Updated: Jun 15, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Doxorubicin-induced ovarian toxicity
Irit Ben-Aharon1, Hadas Bar-Joseph, Galia Tzarfaty
1Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.
Reproductive Biology and Endocrinology : RB&E
|March 6, 2010
Summary
Doxorubicin chemotherapy significantly reduces ovarian size and ovulation rates in mice, indicating potential ovarian toxicity. This study clarifies a mechanism for chemotherapy-induced infertility in young cancer patients.
Area of Science:
- Reproductive Biology
- Oncology
- Toxicology
Background:
- Chemotherapy, including doxorubicin, poses a risk of infertility and premature ovarian failure in young cancer patients.
- Chemotherapy can induce ovarian toxicity by affecting follicles, oocytes, and the overall ovarian structure.
- The specific mechanisms of doxorubicin-induced ovarian toxicity are not fully understood.
Purpose of the Study:
- To investigate the ovarian toxicity of doxorubicin in a preclinical mouse model.
- To elucidate the impact of doxorubicin on ovarian size, weight, follicle populations, and ovulation.
Main Methods:
- Female mice received intraperitoneal injections of doxorubicin (7.5 or 10 mg/kg).
- Ovarian size and weight were assessed via MRI and direct measurement at one day and one month post-treatment.
- Histological analysis included TUNEL and active caspase-3 staining to evaluate apoptosis, alongside follicle counting and categorization.
- Ovulation rates were assessed in superovulated, doxorubicin-treated mice.
Main Results:
- Doxorubicin treatment led to a significant decrease in ovarian size and weight, persisting for one month.
- A marked reduction in ovulation rate was observed one week post-treatment, with partial recovery at one month.
- Histological findings showed positive TUNEL and active caspase-3 staining, indicating apoptosis.
- A significant depletion of secondary and primordial follicles was noted one month after doxorubicin administration.
Conclusions:
- Doxorubicin induces ovarian toxicity through an acute insult, leading to reduced ovulation and ovarian size.
- These findings suggest a potential mechanism for chemotherapy-induced ovarian failure in patients.
- Further research is warranted to develop strategies for mitigating doxorubicin's ovarian toxicity.
Related Concept Videos
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...